Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Document › Details

NorDiag ASA. (3/17/11). "Press Release: NorDiag & Molzym Enter into First Sepsis Agreement".

Organisations Organisation Molzym GmbH & Co. KG
  Group Kompass (Group)
  Organisation 2 Seegene Inc.
  Group Seegene (Group)
Products Product MolYsis sample preparation kit
  Product 2 Arrow DNA isolation device
Person Person Wigstøl, Mårten (Nordiag 200704 CEO)

Molzym has entered into an agreement with Seegene for delivery of reagents based on their molysis technology for Seegene's new sepsis test to be introduced in the near future. Seegene's sepsis test will be executed at their SeePrep sample preparation instrument - an OEM instrument from NorDiag. Sepsis is one of the leading cause of death in hospitals world-wide.

The agreement means that Seegene's new Sepsis test is tailored to NorDiag's sample preparation platform, and that users will have access to a SeePrep instrument to utilize the test. Additionally, Molzym and NorDiag have agreed on a profit agreement regarding delivery of reagents to strategic partners - which means that NorDiag will have a share of the profit after deduction of production costs.

There is an urgent need of a gene based Sepsis test in the market, because it is faster and more précis than traditional cultivation, and time is crucial in order to save lives. "We have great expectations to this concept, based on the expected sensitivity and specificity where Molysis and Arrow technology is combined with Seegenes Magicplex amplification platform says Mårten Wigstøl, CEO of NorDiag.

Complete press release from Seegene and Molzym is attached.

Contact: CEO Mårten Wigstøl Phone. +47 911 65775

About NorDiag:

NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 35.3 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information -

Read the press release from Seegene and Molzym here.

Record changed: 2019-06-09


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Kompass (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top